We have previously shown, in the rat, that neuropathic and inflammatory events produce a neuroplastic change in nociceptor function whereby a subsequent exposure to a proinflammatory mediator (e.g.
prostaglandin E2 ;
PGE2 ) produces markedly prolonged
mechanical hyperalgesia. While the initial approximately 30 min of this prolonged
PGE2 hyperalgesia remains PKA-dependent, it subsequently switches to become dependent on
protein kinase C epsilon (PKCε). In this study we tested the hypothesis that the delayed onset, PKCε-mediated, component of
PGE2 hyperalgesia is generated by the active release of a
nucleotide from the peripheral terminal of the primed nociceptor and this
nucleotide is then metabolized to produce
adenosine, which acts on a Gi-coupled A1
adenosine receptor on the nociceptor to generate PKCε-dependent
hyperalgesia. We report that inhibitors of
ATP-binding cassette transporters, of ecto-5'-phosphodiesterase and ecto-5'nucleotidase (
enzymes involved in the metabolism of
cyclic nucleotides to
adenosine) and of A1
adenosine receptors each eliminated the late, but not the early, phase of
PGE2 -induced
hyperalgesia in primed animals. A second model of
chronic pain induced by transient attenuation of
G-protein-coupled receptor kinase 2, in which the prolongation of
PGE2 hyperalgesia is not PKCε-dependent, was not attenuated by inhibitors of any of these mechanisms. Based on these results we propose a contribution of an autocrine mechanism, in the peripheral terminal of the nociceptor, in the hyperalgesic priming model of
chronic pain.